CBD Life Sciences Inc. CBDL
OTC PK
| 03/31/2024 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 36.19% | -32.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 36.19% | -32.69% | |||
| Cost of Revenue | 73.10% | -36.68% | |||
| Gross Profit | 4.12% | -28.87% | |||
| SG&A Expenses | 72.66% | -86.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.78% | -83.32% | |||
| Operating Income | -122.98% | 91.71% | |||
| Income Before Tax | -122.98% | 91.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -122.98% | 91.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -122.98% | 91.71% | |||
| EBIT | -122.98% | 91.71% | |||
| EBITDA | -578.00% | 98.16% | |||
| EPS Basic | -100.00% | 90.48% | |||
| Normalized Basic EPS | -100.00% | 92.31% | |||
| EPS Diluted | -100.00% | 90.48% | |||
| Normalized Diluted EPS | -100.00% | 92.31% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||